Related Experiment Video

Updated: Aug 23, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

A human single-chain antibody specific for integrin alpha3beta1 capable of cell internalization and delivery of

Antonietta M Lillo1, Chengzao Sun, Changshou Gao

  • 1Department of Chemistry, The Scripps Research Institute and The Skaggs Institute for Chemical Biology, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.

Chemistry & Biology
|July 24, 2004
PubMed

Insights

New antibody-drug conjugates targeting integrin alpha3beta1 show promise for cancer therapy. These Pan10-drug conjugates are cytotoxic at nanomolar concentrations, offering a potential new approach for treating cancers overexpressing this receptor.

Area of Science:

  • Oncology
  • Immunology
  • Bioconjugation Chemistry

Background:

  • Targeted cancer chemotherapy relies on antibodies recognizing cancer-specific surface proteins.
  • Integrin alpha3beta1 is overexpressed on malignant melanoma, prostate carcinoma, and glioma cells.
  • A human single-chain Fv antibody (scFv), Pan10, specific for integrin alpha3beta1, is internalized by cancer cells.

Purpose of the Study:

  • To chemically modify the Pan10 antibody with reactive thiol groups.
  • To conjugate the modified Pan10 scFv to duocarmycin SA analogs.
  • To evaluate the properties and efficacy of the resulting antibody-drug conjugates (ADCs).

Main Methods:

  • Chemical modification of Pan10 scFv to introduce thiol groups.
  • Maleimide conjugation of duocarmycin SA analogs to the modified Pan10.
  • Assessment of conjugate internalization and in vitro cytotoxicity.

Main Results:

  • Successful chemical introduction of reactive thiol groups onto Pan10.
  • Specific conjugation of Pan10 to maleimide-derivatized duocarmycin SA analogs.
  • Pan10-drug conjugates retained the internalization capacity of the parent scFv.
  • Conjugates demonstrated cytotoxicity at nanomolar concentrations.

Conclusions:

  • Pan10-drug conjugates are effectively internalized by cancer cells.
  • These conjugates exhibit potent nanomolar cytotoxicity.
  • Pan10-drug conjugates represent promising candidates for targeted chemotherapy in integrin alpha3beta1-overexpressing cancers.

More Related Videos

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Related Concept Videos

Integrins01:10

Integrins

Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.